Detska Fakultna Nemocnica Kosice
- Address
- lock Available on a paid plan
Detska Fakultna Nemocnica Kosice - Pediatric Hematology-Oncology and Respiratory Center
Detska Fakultna Nemocnica Kosice (Children's Faculty Hospital Kosice) is a specialized pediatric medical center with demonstrated expertise in both hematologic malignancies and respiratory diseases in children and adolescents. The facility participates in international collaborative research protocols, contributing to advancing treatment standards for complex pediatric conditions.
- Acute lymphoblastic leukemia (ALL) treatment protocols with advanced immunotherapy and targeted therapy approaches
- Lymphoblastic lymphoma management using intensive chemotherapy regimens and CNS-directed therapies
- Pediatric asthma research focusing on rescue medication efficacy and exacerbation prevention
The center's research portfolio demonstrates particular strength in pediatric hematologic oncology, participating in major AIEOP-BFM collaborative trials that investigate novel therapeutic agents including bortezomib and blinatumomab for high-risk ALL patients. Their involvement in international protocols for lymphoblastic lymphoma addresses critical questions regarding CNS prophylaxis and treatment intensification strategies. Additionally, the center maintains an active respiratory research program evaluating combination rescue therapy for pediatric asthma patients, reflecting a comprehensive approach to both oncologic and non-oncologic pediatric conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 4 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Pfizer Inc.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Detska Fakultna Nemocnica Kosice
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| B7841007 - An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors | Pfizer Inc. | Phase III | Recruiting | Nov 2022 | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 2 | Unknown | 2018-07-15 | 2019-08-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.